The oroxylin A inhibitor ACTNI reduces the secretion of CCL2 by inhibiting phosphorylation of the focal adhesion kinase (FAK)/STAT3 signaling pathway, which inhibits BC metastasis [62]. The gene discussed is CCL2; the disease is breast cancer.